本工作旨在通过将介孔纳米颗粒掺入其中来开发优化的骨修复支架,从而结合用于细胞生长的生物活性因子并防止快速释放或失去效力。我们合成了生物相容性和可生物降解的支架,设计用于姜黄素(CUR)和重组人骨形态发生蛋白2(rhBMP-2)的受控共递送。将树枝状二氧化硅/二氧化钛介孔纳米颗粒(DSTN)中的活性剂以不同的重量百分比(0、2、5、7、9和10wt%)掺入聚己内酯(PCL)和聚乙二醇(PEG)纳米纤维的基质中,形成CUR-BMP-2@DSTN/PCL-PEG递送系统(分别为S0、S2、S5、S7、S9和S10,数字显示重量百分比)。为了加强形成过程,该系统采用低强度脉冲超声(LIPUS)治疗.采用不同的先进方法来评估身体,化学,和预制脚手架的机械特性,所有这些都证实了纳米粒子的掺入改善了它们的机械和结构性能。它们的亲水性增加了大约25%,通向CA.53%的提高了它们的吸水能力。此外,我们观察到持续释放约97%的CUR和70%的BMP-2的S7(支架7重量%DSTN)超过28天,使用超声波进一步增强。体外研究表明,加速支架生物降解,在S7支架中观察到的最高水平,比对照组高三倍左右。此外,与对照组相比,含DSTN的支架上的细胞活力和增殖增加。总的来说,我们的研究提出了一种有前途的纳米复合支架设计,在结构上有显著的改进,机械,以及与对照组相比的生物学特性,以及受控和持续的药物释放能力。这使得该支架成为先进骨组织工程和再生疗法的引人注目的候选者。
The present work aims to develop optimized scaffolds for bone repair by incorporating mesoporous nanoparticles into them, thereby combining bioactive factors for cell growth and preventing rapid release or loss of effectiveness. We synthesized biocompatible and biodegradable scaffolds designed for the controlled codelivery of curcumin (CUR) and recombinant human bone morphogenic protein-2 (rhBMP-2). Active agents in dendritic silica/titania mesoporous nanoparticles (DSTNs) were incorporated at different weight percentages (0, 2, 5, 7, 9, and 10 wt %) into a matrix of polycaprolactone (PCL) and polyethylene glycol (PEG) nanofibers, forming the CUR-BMP-2@DSTNs/PCL-PEG delivery system (S0, S2, S5, S7, S9, and S10, respectively, with the number showing the weight percentage). To enhance the formation process, the system was treated using low-intensity pulsed ultrasound (LIPUS). Different advanced methods were employed to assess the physical, chemical, and mechanical characteristics of the fabricated scaffolds, all confirming that incorporating the nanoparticles improves their mechanical and structural properties. Their hydrophilicity increased by approximately 25%, leading to ca. 53% enhancement in their water absorption capacity. Furthermore, we observed a sustained release of approximately 97% for CUR and 70% for BMP-2 for the S7 (scaffold with 7 wt % DSTNs) over 28 days, which was further enhanced using ultrasound. In vitro studies demonstrated accelerated scaffold biodegradation, with the highest level observed in S7 scaffolds, approximately three times higher than the control group. Moreover, the cell viability and proliferation on DSTNs-containing scaffolds increased when compared to the control group. Overall, our study presents a promising nanocomposite scaffold design with notable improvements in structural, mechanical, and biological properties compared to the control group, along with controlled and sustained drug release capabilities. This makes the scaffold a compelling candidate for advanced bone tissue engineering and regenerative therapies.